GlassScriptPhysician profile
Maxim E Shuman
NPI 1417053208
$1,838.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $369 · 2021: $654 · 2022: $173.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $638.36 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.45 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $149.35 | 2019-2022 | |
| Neos Therapeutics, LP | $124.55 | 2019 | |
| Cranial Technologies, INC | $112.47 | 2019-2022 | |
| Adlon Therapeutics L.P. | $95.38 | 2020-2021 | |
| Shire North American Group INC | $87.77 | 2019 | |
| Pfizer INC. | $63.09 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $59.54 | 2019-2022 | |
| Glaxosmithkline, LLC. | $48.08 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $46.68 | 2021 | |
| Genentech USA, INC. | $45.92 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $41.71 | 2019 | |
| Sobi, INC | $37.26 | 2021 | |
| Corium, LLC | $35.76 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.06 | 2019 | |
| Mission Pharmacal Company | $13.73 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxim Shuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.